Company data sheet · Legend Biotech
Legend Biotech: eight lost years, and the economy wasn't the reason.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- United States
- Ticker
- LEGN (Nasdaq)
- Sources
- SEC filings (2020–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- October 18, 2026
- From profit to eight straight losses. Legend Biotech lost money every year from 2018 to 2025: $2.2 billion in all.
- It outgrew its own economy many times over. Revenue rose from $0 billion in 2018 to $1 billion in 2025: 20.9 times as much. The US economy, counted the same way in money terms, grew about 45%. Whatever drove it, the economy around it does not account for growth of that size.
- It wasn't the cycle. The losses began in 2018, a year the US economy grew 3.0% and factories added jobs. When a company falls while its economy grows, look inside the company first.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2018 | $0 billion | −$0 billion | |
| 2019 | $0.1 billion | −$0.1 billion | |
| 2020 | $0.1 billion | −$0.3 billion | |
| 2021 | $0.1 billion | −$0.4 billion | |
| 2022 | $0.1 billion | −$0.4 billion | |
| 2023 | $0.3 billion | −$0.5 billion | |
| 2024 | $0.6 billion | −$0.2 billion | |
| 2025 | $1 billion | −$0.3 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.